1 / 73

UTI & Pneumonia Translating Knowledge into Practice

UTI & Pneumonia Translating Knowledge into Practice. PIAS-KT Study Sukhjinder Sidhu Sean Gorman Richard Slavik Tasha Ramsey Sarah Murray Nicole Bruchet. Attendance. Please email Brenda Flood ( brenda.flood@interiorhealth.ca ) if you attended this session

zeph-lawrence
Download Presentation

UTI & Pneumonia Translating Knowledge into Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UTI & PneumoniaTranslating Knowledge into Practice PIAS-KT Study Sukhjinder Sidhu Sean Gorman Richard Slavik Tasha Ramsey Sarah Murray Nicole Bruchet

  2. Attendance • Please email Brenda Flood (brenda.flood@interiorhealth.ca) if you attended this session • Please email Brenda Flood (brenda.flood@interiorhealth.ca) if you view this presentation online at a later date

  3. THANK YOU! • YOU SURPASSED OUR PROJECTED PARTICIPATION RATE FOR THE PRE-QUIZ! • STAY TUNED FOR A POST-QUIZ THAT WILL BE SENT OUT IN MID-MARCH • THANK YOU TO TASHA RAMSEY FOR HER EXPERT REVIEW OF THIS PRESENTATION

  4. Speaker Disclosure • The speakers have no actual or potential conflicts of interest to disclose

  5. Outline • PIAS-KT Study Overview • Local Opinion Leaders • Prevalence and Impact of UTIs & Pneumonia • Antimicrobial Stewardship • Key Pharmacist Interventions for UTIs & Pneumonia • DTP Tracker Data for UTIs & Pneumonia • UTIs & Pneumonia Therapeutics • When to treat with antibiotics and When Not to treat? • What antibiotics to initiate and Why? • When, How, and Why to de-escalate antibiotics? • How long to treat with antibiotics?

  6. Objectives • To review the pharmaceutical care of patients with UTIs & Pneumonia including: • Key pharmacist interventions • Indications for antibiotic therapy • Initial empiric antibiotic therapy recommendations • Antibiotic de-escalation strategies • IV to PO step-down considerations • Duration of antibiotic therapy

  7. PIAS-KT Study Overview Intervention PRE phase POST phase Knowledge Knowledge Behavior Behavior Behavioral Change Strategies Jan 30 – Mar 14, 2014 DTP/DSEM DTP KPI/DSEM KPI Jul 1-Dec 31,2013 DTP/DSEM DTP KPI/DSEM KPI Jan 1-Jun 30, 2014 Quiz Jan 17-30, 2014 Quiz Mar 17-28, 2014 1. Audit & Feedback 2. Local opinion leaders 3. Educational meetings 4. Educational outreach 5. Printed education materials 6. Reminders

  8. Local Opinion Leaders • KGH – Dawn Robb • RIH – Kim Winters • PRH/SOH – Orysya Fetterly • VJH – Chelsea Argent • SLH/OMH – Ian Petterson • KBH/KLH – Michael Conci • EKH/GDH – Darren Feere

  9. Prevalence & Impact of UTIs Prevalence • Approximately 4,000,000 UTIs/year in Canada • Affects 20%of women between 15-29 yo • Number 1 healthcare-associated infection • 16thmost common non-surgical reason for IH admission Impact • 660 cases and 3200acute bed-days at IH • Hospital-acquired UTIs associated with extra day of hospitalization • Up to 25% of patients with UTI receive inappropriate therapy • Up to 50% of patients with asymptomatic catheter-associated bacteriuria are treated with antibiotics (which is inappropriate) Mayo Clin Proc 2007;82:181-5.; Can J Infect Dis Med Microbiol 2005;16:166-70.

  10. Prevalence & Impact of Pneumonia Prevalence • Approximately 170,000 cases of CAP each year in Canada • HAP/VAP is 2nd most common nosocomial infection in Canada • 5th most common non-surgical reason for IH admission Impact • 1300 cases and 7000acute bed-days at IH each year • CAP is the leading infectious cause of death • Up to 15% of patients with CAP receive inadequatetherapy • Up to 75%of patients with HAP/VAP receive inadequate therapy Clin Infect Dis 2005;41:1709-16.; Postgrad Med 2010;122:130-141.

  11. Antimicrobial Stewardship Definition • An activity (or activities) that includes • Appropriate antibiotic selection • Appropriate antibiotic dosing • Appropriate antibiotic route selection • Appropriate antibiotic duration of therapy Clin Infect Dis 2007;44:159-77.

  12. Antimicrobial Stewardship Goals • Optimize clinical outcomes by ensuring effective antimicrobial therapy • Minimize collateral damage from antimicrobials • Antimicrobial resistance • Antimicrobial toxicity • Costs of inappropriate antimicrobial use • Superinfections (e.g. Clostridium difficile) Clin Infect Dis 2007;44:159-77.

  13. Clinical Pharmacists’ Role in Antimicrobial Stewardship ANTIMICROBIAL STEWARDSHIP PHARMACEUTICAL CARE

  14. Urinary Tract Infection Key Pharmacist Interventions • Initiate appropriate antibiotics for symptomatic UTI • Discontinue empiric antibiotics started for UTI that are not indicated • De-escalate antibiotics for UTI based on C&S data and clinical response • Perform IV to PO step-down of antibiotics for UTI • Promote appropriate duration of antibiotic therapy for UTI IH UTI Key Pharmacist Interventions, April 21, 2011

  15. Pneumonia Key Pharmacist Interventions • Initiate appropriate antibiotics for pneumonia • Discontinue empiric antibiotics started for pneumonia that are not indicated • De-escalate antibiotics for pneumonia based on C&S data and clinical response • Perform IV to PO step-down of antibiotics for pneumonia • Promote appropriate duration of antibiotic therapy for pneumonia IH Pneumonia Key Pharmacist Interventions, April 21, 2011

  16. Project Alignment • CPhA “Blue Print” for Pharmacy Practice • CSHP “Vision 2015” • Canadian Clinical Pharmacy KPI Collaborative • Accreditation Canada • MOHS KRAs and CCM groups • IH SET goals, objectives • IH Pharmacy Clinical Priorities

  17. DTP Tracker Data - UTI • UTI ranks #6 in disease prevalence for all Rx interventions • UTI ranks #3 in disease prevalence for 8 DSEM interventions • UTI ranks #2 in disease prevalence for key pharmacist interventions

  18. DTP Tracker Data - UTI • AIMS study showed a statistically significant, clinically important increase after DSEMs • DSEM DTP/total DTP (27.9% to 31.9%, p<0.05) • KPI/total DTP (21.7% to 25.8%, p<0.05) • In UTI subgroup, AIMS failed to show a statistically significant benefit • DSEM DTP/total DTP (3.91% to 3.93%, p=NS) • KPI/total DTP (3.82% to 4.61%, p=NS)

  19. DTP Tracker Data - Pneumonia • Pneumonia ranks #3 in disease prevalence for all Rx interventions • Pneumonia ranks #2 in disease prevalence for 8 DSEM interventions • Pneumonia ranks #3 in disease prevalence for key pharmacist interventions

  20. DTP Tracker Data - Pneumonia • In Pneumonia subgroup, AIMSfailed to show a statistically significant benefit • DSEM DTP/total DTP (4.75% to 4.90%, p=NS) • However, in Pneumonia subgroup, AIMS demonstrated a statistically significant REDUCTION • KPI/total DTP (5.07% to 3.94%,p=0.016)

  21. Pharmaceutical Care of UTI and Pneumonia

  22. UTI Pharmaceutical CareOutline • When and When Not to treat with antibiotics? • Whatantibiotics to initiate and Why? • When, How, and Why to de-escalateantibiotics? • How long to treat with antibiotics?

  23. What Makes a UTI ‘Complicated’? • Patients with structural or functional abnormalities of the genitourinary tract • Obstruction • Instrumentation (including catheters) • Impaired voiding • Metabolic abnormalities • Immunocompromised • Men Can J Infect Dis Med Microbiol 2005;16:349-60.

  24. UTI“Why should antibiotics be initiated?” •  duration of symptoms •  abscesses, metastatic infection, septic shock, AKI Clin Infect Dis 2005;40:643-54.

  25. UTI“When should antibiotics be initiated?” • Clinical manifestations of cystitis • Dysuria, frequency, urgency, suprapubic pain, hematuria • Clinical manifestations of pyelonephritis • Above symptoms together with fever (>38°C), chills, flank pain, costovertebral angle tenderness, and nausea/vomiting • Asymptomatic bacteriuria in pregnancy

  26. Cystitis at IH“When should antibiotics be initiated?” “If clinically feasible, initiation of antimicrobial therapy should be delayed until results of urine culture are available” Can J Infect Dis Med Microbiol 2005;16:349-60.

  27. UTI at Interior Health“What antibiotics should be initiated and why?” Organisms Associated with Urinary Tract Infections Infection 2007;35:150-3. (Calgary Data 2004-5)

  28. UTI at Interior Health“What antibiotics should be initiated and why?” PO options IV options *E. coli Susceptibilities at IH 2012

  29. UTI at Interior Health“What antibiotics should be initiated and why?” *Enterococcus Susceptibilities at IH 2012

  30. UTI at Interior Health“What antibiotics should be initiated and why?” • Risk Factors for Antibiotic Resistant UTIs • Abx exposure (especially to TMP/SMX or FQ) in past 3 months • Travel to endemic area • Previous multi-drug resistant UTI Clin Infect Dis 2005;40:643-54.

  31. UTI at Interior Health“What antibiotics should be initiated and why?” • Oral Antibiotic Selection • Oral antibiotics are first line for cystitis • Oral antibiotics are first line for uncomplicated pyelonephritis (not acutely ill) • IV Antibiotic Selection • Unable to tolerate oral therapy (nausea/vomiting/ileus) • Impaired GI absorption • Hemodynamic instability (acutely ill) • Infecting organism resistant to available oral options Clin Infect Dis 2005;40:643-54., Can J Infect Dis Med Microbiol2005;16:349-60.

  32. Complicated Cystitis at IH“What antibiotics should be initiated?” “Oral antimicrobial therapy is appropriate for most episodes” Can J Infect Dis Med Microbiol 2005;16:349-60.

  33. Uncomplicated Cystitis at IH“What antibiotics should be initiated?” Recommendations for Empiric Therapy • Nitrofurantoin 100 mg PO BID x 5 days (CrCl ≥ 40 mL/min) • Trimethoprim/Sulfamethoxazolei DS PO BID x 3 days • Cefixime400 mg PO Daily x 3 days • Amoxicillin/Clavulanate875 mg PO BID x 3 days • Amoxicillin/Clavulanate500 mg PO TID x 3 days

  34. Complicated Cystitis at IH“What antibiotics should be initiated?” Recommended Empiric Oral Options 1st Line • Cefixime 400 mg PO Daily x 7-14 days • Amoxicillin/Clavulanate 875 mg PO BID x 7-14 days • Amoxicillin/Clavulanate 500 mg PO TID x 7-14 days • Trimethoprim/Sulfamethoxazolei DS PO BID x 7-14 days 2nd Line (high prevalence resistance) • Ciprofloxacin 500 mg PO BID x 7-14 days

  35. Complicated Cystitis at IH“What antibiotics should be initiated?” Recommended Empiric IV Options • Ampicillin + Gentamicin • Ampicillin + Ceftriaxone • Piperacillin/Tazobactam +/- Gentamicin

  36. Uncomplicated Pyelonephritis at IH“What antibiotics should be initiated and why?” Recommend Empiric Oral Therapy • Same as for uncomplicated cystitis EXCEPT: • No nitrofurantoin • Longer duration of therapy (7-14 days)

  37. Uncomplicated Pyelonephritis at IH“What antibiotics should be initiated and why?” Recommended Empiric IV Therapy for Acutely Ill Patients • Gentamicin 5-7 mg/kg/day IV OR • Ceftriaxone 1-2G IV daily

  38. Complicated Pyelonephritis at IH“What antibiotics should be initiated and why?” Recommended Empiric Oral Options • Same as for complicated cystitis 1st Line • Cefixime 400 mg PO Daily x 7-14 days • Amoxicillin/Clavulanate 875 mg PO BID x 7-14 days • Amoxicillin/Clavulanate 500 mg PO TID x 7-14 days • Trimethoprim/Sulfamethoxazolei DS PO BID x 7-14 days 2nd Line (high prevalence resistance) • Ciprofloxacin 500 mg PO BID x 7-14 days

  39. Complicated Pyelonephritis at IH“What antibiotics should be initiated and why?” Recommended Empiric IV Options • Same as for complicated cystitis • Ampicillin + Gentamicin • Ampicillin + Ceftriaxone • Piperacillin/Tazobactam +/- Gentamicin

  40. Asymptomatic Bacteriuria in Pregnancy “What antibiotics should be initiated and why?” Recommended Antibiotic Therapy • Wait for results of screening urine C&S • Select narrowest spectrum agent that is safe in pregnancy • Amoxicillin/Clavulanate • Amoxicillin • Cefixime • Cephalexin • Nitrofurantoin (avoid in 3rd trimester) • TMP/SMX (avoid in 1st and 3rd trimesters)

  41. UTI Therapeutics“What is antibiotic de-escalation and why is it important?” • Antibiotic De-escalation • Replace empiric broad-spectrum regimen with a more narrow spectrum regimen • Organism identified with susceptibilities • Intended to reduce collateral damage • De-escalation for UTIs is under-performed Infection 2013;41:211-14.

  42. UTI Therapeutics“When and Howshould antibiotics be de-escalated?” • When to de-escalate • Once urine C&S known • No other suspected infections • No patient-limiting factors (e.g. allergy) Infection 2013;41:211-14.

  43. UTI Therapeutics“When and Howshould antibiotics be de-escalated?” • How to de-escalate • Broad spectrum to narrowest spectrum • Narrowest spectrum with  collateral damage risk Examples Infection 2013;41:211-14.

  44. UTI Therapeutics“How should antibiotics be de-escalated?” • IV to PO Step-Down • Tolerates oral intake • No factors affecting absorption • Hemodynamically stable • If acutely ill pyelonephritis and considering PO β-lactam, patient should receive at least 1 dose of Ceftriaxone OR Aminoglycoside Infection 2013;41:211-14.

  45. Interior Health IV to PO Step-Down Policy • Pharmacists Have IV-PO Step-Down Authority • Applies to Ciprofloxacin/Moxifloxacin • Duration IV antibiotics: ≥ 48 hours • Tolerating other PO medications, fluids, or foods x 12 hours • No potential problems with absorption • Clinically stable (stable BP, resolving fever/afebrile, adequate urine output, absence of encephalopathy, WBC normal or normalizing) • Exclusions • Febrile neutropenia, gram negative bacteremia, CNS infections, septic shock, severe cellulitis InsideNet– Pharmacist managed IV to PO conversion program (2006)

  46. UTI Therapeutics“How long to treat with antibiotics?” • Uncomplicated cystitis • 3-7 days (5-7 days for nitrofurantoin) • Complicated cystitis • 7-14 days • Pyelonephritis • 7-14 days

  47. Candida-Associated Cystitis • Indications for treatment • Symptomatic cystitis • Asymptomatic, but high risk (neutropenia, planned urologic manipulation) • Recommended treatment • Fluconazole 200-400 mg PO daily x 14 days • Amphotericin 0.3-0.6 mg/kg IV x 7 days (2nd line) Clin Infect Dis 2009;48:503-35.

  48. Pneumonia Pharmaceutical CareOutline • Whenand When Not to treat with antibiotics? • Whatantibiotics to initiate and Why? • When, How, and Why to de-escalateantibiotics? • How long to treat with antibiotics?

  49. IH Pneumonia DSEM

  50. Pneumonia When and Why Antibiotic Treatment? • Physician/NP Diagnosis • Varies depending on outpatient/inpatient • Chest x-ray infiltrates PLUS • Fever, purulent secretions, elevated WBC • Other clinical manifestations: dyspnea, pleuritic chest pain • Consequences of Pneumonia • Reduced survival • Increased risk of ICU admission • Prolonged length of hospitalization Clin Infect Dis 2007;44:sS.; Pneumonia DSEM 2008.

More Related